top stories

Trump an­nounces picks for FDA, CDC; No­var­tis seeks bolt-on deals, rais­es guid­ance; RFK Jr., Elon Musk may find ban­ning ads dif­fi­cult; and more

Yesterday
Weekly

For CDC, Trump picks Dave Wel­don, a for­mer con­gress­man who pushed for vac­cine in­jury claims

Yesterday
People
Pharma

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

Yesterday
People
FDA+

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Yesterday
Pharma
FDA+

Latest

Sanofi in­tro­duces new 340B pay­ment mod­el — re­port

Yesterday
Pharma
Law

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Yesterday
Pharma
Law

Sen­ate Ju­di­cia­ry Com­mit­tee ad­vances patent bill with new pro­tec­tions for phar­ma chal­lenges

Yesterday
Pharma
Law

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Yesterday
Pharma

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

2 days ago
Deals
Pharma

Lex­i­con ends com­mer­cial work to fo­cus on R&D

2 days ago
People
Pharma
see latest stream
People

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

3 days ago

Pfiz­er taps on­col­o­gy head Boshoff as Dol­sten's chief sci­en­tif­ic of­fi­cer suc­ces­sor

4 days ago

Ex­clu­sive: For­mer Pfiz­er com­mer­cial chief An­gela Hwang to join Flag­ship

4 days ago
Financing

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

2 days ago

Ven­rock adds $500M to health­care in­vest­ing strat­e­gy af­ter out­lin­ing 10th fund in Jan­u­ary

3 days ago

Car­olyn Bertozzi’s lat­est biotech de­buts with $30M seed round and a sug­ary spin on im­munother­a­py

4 days ago
Startups

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

4 days ago

For­mer NCI di­rec­tor teams up with se­r­i­al en­tre­pre­neur for $70M VC fund tar­get­ing 'su­per-ear­ly' sci­ence

5 days ago

At­las Ven­ture tar­gets $450M for 14th biotech fund, the same size as its 2022 raise

6 days ago
Deals

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

3 days ago

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

3 days ago

23andMe inks new re­search part­ner­ship as it winds down in­ter­nal drug de­vel­op­ment ef­forts

4 days ago

In FocusSee all

Law­mak­ers are pok­ing holes in phar­ma's fa­vorite new way to mar­ket med­i­cines

5 days ago
Pharma
Health Tech

A rare neu­ro­log­i­cal dis­ease is Sage’s last, best hope af­ter fail­ures in de­pres­sion

5 days ago
R&D
Pharma

Yorvipath’s ap­proval show­cas­es bio­phar­ma’s in­ter­est in rare en­docrine dis­or­der

Last week
Startups
R&D

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

3 weeks ago
FDA+

Endpoints Standouts

How the world's biggest phar­ma and biotech com­pa­nies paid their typ­i­cal work­er in 2023

4 months ago
People
Pharma

In biotech's un­even re­cov­ery, 50 star­tups raised megarounds in first half of 2024

4 months ago
Financing
Startups

Bio­phar­ma lead­ers chart­ing a path for the in­dus­try's LGBTQ+ com­mu­ni­ty

5 months ago
People
Special

Pe­ter Marks sin­gle-hand­ed­ly ap­proved Sarep­ta’s gene ther­a­py — what does that mean for every­one else?

5 months ago
Pharma
Cell/Gene Tx

Peer review See all

Nov
22

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Nov
15

ALX On­col­o­gy hires Genen­tech, Mi­rati vet as CMO; Af­ter Car­mot, Heather Turn­er has three new roles on tap

Nov
8

Leg­end names a pres­i­dent of Carvyk­ti; No­vo Nordisk's top North Amer­i­ca ex­ec is step­ping down

Nov
1

Bio­gen brings in med­ical chief as CFO plans re­tire­ment; Macro­Gen­ics CEO an­nounces de­par­ture

Oct
25

Chi­nook alums re­unite fol­low­ing ex­it to No­var­tis; The first board ap­point­ment for Re­cur­sion’s Chris Gib­son

Pharma channel feed

2 days ago

With years­long re­or­ga­ni­za­tion be­hind it, No­var­tis in­creas­es its sales guid­ance

No­var­tis’ re­or­ga­ni­za­tion is pay­ing off, CEO Vas Narasimhan told in­vestors at an event Thurs­day in Lon­don.

READ MORE

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

2 days ago
FDA+

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

3 days ago
latest in Pharma

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

3 days ago
R&D

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

3 days ago
FDA+

GSK plots reg­u­la­to­ry fil­ings for PBC itch af­ter pos­i­tive Phase 3 read­out

4 days ago
FDA+

NICE has 'done all we can' to ne­go­ti­ate for En­her­tu cov­er­age, reaf­firms de­ci­sion not to rec­om­mend

4 days ago

FDA re­jects Astel­las’ ef­fort to sup­port longer use of eye drug Iz­er­vay 

4 days ago
FDA+
see latest stories

Marketing channel feed

2 days ago

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

As the health­care pri­or­i­ties of Pres­i­dent-elect Don­ald Trump and his HHS pick Robert F. Kennedy Jr. take shape, one idea gain­ing steam is a ban on di­rect-to-con­sumer phar­ma­ceu­ti­cal ...

READ MORE

FDA says Merz's so­cial me­dia pro­mo­tion with Nate Berkus is 'mis­lead­ing'

Last week
Pharma

Val­ne­va and Pfiz­er eye 2027 launch for part­nered Ly­me dis­ease vac­cine

Last month
Pharma
latest in Marketing

UK watch­dog crit­i­cizes Mod­er­na for Covid-19 tri­al's use of What­sApp to dan­gle pay­ments to chil­dren

Last month
Pharma

FDA crit­i­cizes Ab­b­Vie's 'mis­lead­ing' ad with Ser­e­na Williams

2 months ago
Pharma
FDA+

Up­dat­ed: Madri­gal fi­nal­ly re­veals first wave of sales for MASH drug Rezd­if­fra

3 months ago
Pharma

RSV mar­ket pres­sure leads to slow­er launch for Mod­er­na's vac­cine

3 months ago
Pharma

Verona inks fi­nanc­ing deal worth up to $650M ahead of COPD de­ci­sion

6 months ago
Financing
see latest stories

FDA+ channel feed

2 days ago

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

Mem­bers of an FDA ad­vi­so­ry com­mit­tee were not asked to vote Thurs­day on As­traZeneca’s an­ti­co­ag­u­lant re­ver­sal drug An­dexxa, but they did raise sev­er­al safe­ty and ef­fi­ca­cy con­cerns.

READ MORE

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

3 days ago
AI
Health Tech

Ahead of ad­comm, FDA rais­es safe­ty ques­tions for As­traZeneca’s re­ver­sal agent for life-threat­en­ing bleeds

4 days ago
Pharma
latest in FDA+

Chi­nese drug­mak­er re­ceives FDA warn­ing let­ter af­ter man­age­ment hin­dered in­spec­tion

4 days ago
Manufacturing

Syn­dax's Re­vu­forj wins FDA ap­proval in ag­gres­sive form of leukemia

5 days ago
Pharma

FDA of­fers more guid­ance on de­vel­op­ing cell and gene ther­a­pies

5 days ago
Cell/Gene Tx

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

Last week
Editor's note

Eli Lil­ly sues the US gov­ern­ment over its pro­posed 340B re­bate mod­el

Last week
Pharma
Law
see latest stories

Manufacturing channel feed

2 days ago

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

LON­DON — Thou­sands of del­e­gates flood­ed in­to the nar­row cor­ri­dors of the Wal­dorf Hilton this week to at­tend the Jef­feries Lon­don Health­care Con­fer­ence. It was so busy that at one point, ...

READ MORE

Sam­sung Bio's new $668M client; Sanofi ex­pands a fac­to­ry in France

2 days ago

Evotec gains on Halozyme's takeover pro­pos­al

Last week
Deals
latest in Manufacturing

Eu­ro­pean Com­mis­sion seeks bio­phar­ma feed­back on No­vo-Catal­ent deal — re­port

Last week
Deals

Lon­za ex­pands bio­con­ju­gates fac­to­ry; WuXi Bio adds ca­pac­i­ty in Ger­many 

Last week

No­vo Nordisk to phase out its pro­duc­tion of hu­man in­sulin pens glob­al­ly

Last week

Mer­ck KGaA’s life sci­ence unit is still feel­ing the Covid de­mand de­cline

Last week
Pharma

Drug in­spec­tor at­tri­tion leads to 'many few­er' checks than 2016 peak, GAO says

Last week
FDA+
see latest stories
A service from the Financial Times